Champignon Brands continues to work with the BC Secutiries Commission to complete its disclosure review.
Champignon Brands continues to work with the BC Secutiries Commission to complete its disclosure review.
Mydecine is planning to spin out its U.S. legacy cannabis assets.
Compass Pathways has set the terms for its IPO, targeting a valuation at or about $544.1 million.
Aion Therapeutic Inc. has filed several plant-based patents with the USPTO.
Numinus seeks to raise CAD$4.0 million at an offering price of CAD$0.25 per unit.
Calgary-based Magic Med Industries has raised CAD$1,642,880 from the sale of 6,571,520 shares.
Novamind Ventures' new CMO has led over 100 clinical trials and currently serves as a Coordinating Investigator for MAPS.
Champignon Brands advises that the BCSC has revoked its original cease trade order (June 19, 2020), but a replacement order remains in effect.
Certain large Mydecine shareholders have entered into a voluntary lock-up, covering 52,908,420 common shares.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now